SCHEMBL30962656

SCHEMBL30962656

COc1nc(Nc2ccc(C3CCN(C)CC3)c(C)c2)ncc1C(=O)Nc1c(Cl)cccc1C#N

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 1/20 0.49
▸ SRC P12931 9/20 0.45
▸ TNK2 Q07912 1/20 0.44
▸ SIK1 P57059 2/20 0.44
▸ SIK2 Q9H0K1 2/20 0.44
▸ SIK3 Q9Y2K2 2/20 0.44
▸ PTK2 Q05397 1/20 0.44
▸ TBK1 Q9UHD2 4/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ LCK P06239 2/20 0.43
▸ KDR P35968 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ TEK Q02763 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ HCK P08631 1/20 0.42
▸ FGFR1 P11362 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30962713 0.94 WEE1 (0.49) WEE1SRCTNK2SIK1SIK2
SCHEMBL27313416 0.93 WEE1 (0.54) WEE1SRCTNK2SIK1SIK2
SCHEMBL30962584 0.91 SIK1 (0.44) WEE1SIK1SIK2SIK3PTK2
SCHEMBL27313755 0.91 SIK1 (0.44) WEE1SIK1SIK2SIK3PTK2
SCHEMBL27313419 0.91 SRC (0.53) WEE1SRCTNK2SIK1SIK2
SCHEMBL30962699 0.91 SRC (0.53) WEE1SRCTNK2SIK1SIK2
SCHEMBL30962868 0.90 WEE1 (0.51) WEE1SRCTNK2SIK1SIK2
SCHEMBL30962787 0.89 WEE1 (0.51) WEE1SRCTNK2SIK1SIK2
SCHEMBL30962653 0.89 LCK (0.48) WEE1SRCSIK1SIK2SIK3
SCHEMBL30962799 0.89 SIK1 (0.54) WEE1SRCTNK2SIK1SIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 — — WO disclosed
Send feedback